Journal Finder

ASN Neuro is an open access, peer-reviewed journal uniquely positioned to provide investigators with the most recent advances across the breadth of the cellular and molecular neurosciences. The official journal of the American Society for Neurochemistry, ASN Neuro is dedicated to the promotion, support, and facilitation of communication among cellular and molecular neuroscientists of all specializations. The open access platform and comprehensive scope of the journal allow for rapid dissemination of current research across disciplines to contribute to a complete approach to issues pertaining to the nervous system. High-quality research articles and reviews in such areas as neurochemistry and biology, neurogenetics, glial cells and function, neurodevelopment, neurodegeneration and repair, neuroimmunity, signaling, and other neuro- or glial-related topics are encouraged for submission. There is no charge for submitting a paper to ASN Neuro. Upon acceptance of your manuscript, you will be charged a one-time Article Processing Charge (APC). This fee covers the cost of publication and ensures that your article will be freely available.

The journal 'Acta Neurochirurgica' publishes papers dealing with clinical neurosurgery - diagnosis and diagnostic techniques, operative surgery and results, postoperative treatment - or with research work in neuroscience where underlying questions or results are of neurosurgical interest. As official organ of the European Association of Neurosurgical Societies the journal publishes all announcements of the E.A.N.S. and reports on the activities of its member societies. In addition to the regular journal, 'Acta Neurochirurgica' publishes 3-4 supplement volumes per year. These comprise proceedings of international meetings or other material of general neurosurgical interest.

Peer-reviewed and published quarterly, Acta Neurologica Belgicapresents original articles in the clinical and basic neurosciences, and also reports the proceedings and the abstracts of the scientific meetings of the different partner societies. The contents include commentaries, editorials, review articles, case reports, neuro-images of interest, book reviews and letters to the editor.Acta Neurologica Belgica is the official journal of the following national societies:

Belgian Neurological SocietyBelgian Society for NeuroscienceBelgian Society of Clinical NeurophysiologyBelgian Pediatric Neurology SocietyBelgian Study Group of Multiple SclerosisBelgian Stroke CouncilBelgian Headache SocietyBelgian Study Group of Neuropathology

Acta Neurologica Scandinavica aims to publish manuscripts of a high scientific quality representing original clinical, diagnostic or experimental work in neuroscience. The journla's scope is to act as an international forum for the dissemination of information advancing the science or practice of this subject area. Papers in English will be welcomed, especially those which bring new knowledge and observations from the application of therapies or techniques in the combating of a broad spectrum of neurological disease and neurodegenerative disorders. Relevant articles on the basic neurosciences will be published where they extend present understanding of such disorders. Priority will be given to review of topical subjects. Papers requiring rapid publication because of their significance and timeliness will be included as 'Clinical commentaries' not exceeding two printed pages, as will 'Clinical commentaries' of sufficient general interest. Debate within the speciality is encouraged in the form of 'Letters to the editor'. All submitted manuscripts falling within the overall scope of the journal will be assessed by suitably qualified referees. Submit your manuscript online.

Acta Neuropathologica´s mission is to publish the best articles on pathology and pathogenesis of neurological disease. The journal focuses on structural and molecular neuropathology using human tissue, animal models and in vitro systems.

The journal publishes Original Papers, Review Articles, Case Reports and Scientific Correspondence.

Six reasons for publishing your best paper in Acta Neuropathologica:

High impact: 9.730 (IF 2012)

Wide distribution: more than 6,000 institutions worldwide having full text access.

Efficient handling: 12 days between submission and first decision.

Fast publication: 10 days between acceptance and online publication.

Commitment to fairness: author feedback program.

Cost-free printing: no page charges - free color figures.

Acta Neuropathologica Communications publishes experimental and descriptive papers on the pathology of nervous system and skeletal muscle disorders and on mechanisms of neurological disease using morphological, molecular and cell biology methods.

Acupuncture in Medicine aims to promote the scientific understanding of acupuncture and related treatments by publishing scientific investigations of their effectiveness and modes of action as well as articles on their use in health services and clinical practice.Acupuncture in Medicine is aimed at Western-trained physicians and other health professionals. The Western understanding of neurophysiology and anatomy is used to interpret the effects of acupuncture. The Journal uses the term 'Western medical acupuncture' and largely restricts its published articles to this Western approach. Evidence-based articles on traditional acupuncture (both clinical and theoretical) will, however, be considered. The editorial board welcomes scientific reports, systematic and general reviews, audits, case reports, descriptive and educational papers and other articles that may be of interest to readers.

Advances in Autism (AIA) builds and disseminates evidence on the health and care aspects and outcomes of autistic people, with the goal to inform researchers and professionals; improving the quality of life for those living on the autistic spectrum.

Alzheimer Disease and Associated Disorders is a leading international forum for reports of new research findings and new approaches to diagnosis and treatment. Contributions fall within all relevant scientific fields and clinical specialties, including neurobiology, neurochemistry, molecular biology, neurology, neuropathology, neuropsychology, psychiatry, gerontology, and geriatrics. Rigorous peer review of articles is ensured by an international Editorial Advisory Board of eminent scientists and clinicians. Website: www.alzheimerjournal.com.

The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.

Given the growing number of specialized manuscripts in the field of Alzheimer's and dementia research, DADM will provide an expanded platform to provide a) rapid communication and publication that facilitate cross-fertilization of ideas, b) integrating and translating knowledge across disciplines; disseminating basic and clinical information necessary for optimal translation of research into practical applications and interventions, c) increase knowledge in diverse areas of studies with potentials/implications for practical application related to early detection and/or interventions, d) formulating crucial experiments necessary for the rigorous testing of theories or their predictions, and e) identifying promising new directions of research and providing the impetus or the scientific foundation for new initiatives on interventions.

The mission of Alzheimer's & Dementia: Journal of the Alzheimer's Association is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation. The journal publishes the results of studies in: behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy. Content emphasizes interdisciplinary investigations, integrative/translational articles, related to: etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services. The journal publishes • comprehensive reviews; • research articles; • information on clinical trials; • short reports;• in-depth perspectives/open-peer commentaries; • theoretical and/or translational papers that attempt integrate knowledge across discipline;• history & politics of science/brief biographies and, • abstracts of papers presented at international meetings. Negative results, particularly clinical trials, are published as short communications.The ultimate objective is to create a novel forum for: • rapid communication of new findings, ideas or perspectives; • disseminating knowledge, across the spectrum of basic to clinical studies, necessary for optimal translation of research findings into practical applications/interventions; • integrating knowledge across disciplines; • increase knowledge in diverse disciplines to promote early detection/diagnosis and/or interventions; • formulating new theories and/or strategies for the rigorous testing of theories or their predictions; • identifying promising new directions of research and, • providing the scientific impetus for new initiatives; or public policies concerning research on prevention and new models of health services.Alzheimer's & Dementia is indexed/abstracted in Index Medicus/MEDLINE, Scopus, Science Citation Index Expanded (SciSearch®), Current Contents®/Clinical Medicine, Neuroscience Citation Index®, and Journal Citation Reports/Science Edition.

Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.

Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI) is an open access, peer-reviewed, journal from the Alzheimer's Association® that covers translational research and clinical therapeutics for Alzheimer's disease, dementia and other age-related conditions affecting cognition, memory, and behavior. The journal will provide a rapid method for communication among a multidisciplinary clinical research audience involving the range of therapeutic interventions (e.g., drugs, biologicals, devices, and psychotherapeutic, psychosocial, and non-pharmacological modalities) from preclinical development to late stage trials and health technology assessment.

The focus is original, feature length research articles, systematic reviews, metaanalyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that advance the prevention and treatment of Alzheimer's disease, dementia, and cognitive impairment. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurology, psychiatry, clinical psychology, bioinformatics, and health policy as they apply to preclinical and clinical therapeutics. It will focus on discovery, therapeutic development, clinical pharmacology, preclinical studies, and the application of neuropsychology, clinical ratings, clinical trials methods, neuroimaging, biomarkers, clinical research informatics, and other interdisciplinary approaches to clinical therapeutics and outcomes.

Given the growing number of specialized manuscripts in the field of Alzheimer's and dementia research, TRCI provides an expanded platform for the publication of clinical translational research. TRCI encourages the submission of manuscripts that describe preclinical research with a potential for clinical application, research from early human experimentation (experimental medicine) that may advance clinical treatment and prevention of Alzheimer pathology, neurodegeneration, and cognitive impairment.

Like Alzheimer's & Dementia, TRCI will publish manuscripts describing public health research with the potential for application for disease prevention or clinical therapeutics that bridges the laboratory and clinical settings, and laboratory studies of novel therapeutic interventions and new treatment paradigms. Expanding on the growing number of submissions to Alzheimer's & Dementia, TRCI will provide a rapid communication vehicle for manuscripts that focus on translation and clinical research methods, procedures, protocols, analytical approaches and regulatory science.

The American Journal of Alzheimer's Disease and Other Dementias® (AJADD) is for and by professionals on the frontlines of Alzheimer's care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, healthcare administrators, and other related healthcare specialists who deal with patients having dementias and families everyday. In every issue, you will find down-to-earth clinical information on * Practical medical, psychiatric, and nursing issues such as assessment and management of problem behaviors, communication difficulties, dealing with delusions and other psychotic features, apathy, effects of physical activity, integrated treatment approaches, new and changing pharmacotherapies, orientation behaviors, and hospice use. AJADD also includes information on management of concurrent medical issues in the patient with dementia. * New and forthcoming diagnostic tools such as computerized testing for mild cognitive impairment and other aspects of cognitive testing, as well as high technology resources for sophisticated disease characterization. AJADD also provides information on the clinical features and management of non-Alzheimer's dementias. * Psychosocial issues such as dealing with staff caregivers' distress, improving caregivers' communication skills, helping patients and families to deal with a diagnosis of Alzheimer's disease or another dementia, and patients' perceptions and preferences. * Practice-oriented clinical research from the frontiers of neurology and genetics, including sleep-wake states, targeting glutamate excitotoxicity, cholesterol and apolipoprotein E, and other aspects of the underlying biology that causes the symptoms of dementia. AJADD also reports on the latest clinical trials that focus on medications for the symptoms of dementia and the disease process. * Administrative and legal issues such as coding, consumer evaluation of adult day-care services, cost-effectiveness of special care units, dangerous wandering, end-stage dementia, informed consent, Medicare coverage for cognitively impaired residents, supervision of high-risk fall dementia patients, and vulnerable populations and avoidable hospitalizations.By 2025, it is estimated that there will be about 34 million people in the world with some form of Alzheimer's disease or other dementia. To stay ahead of the latest research, clinical practices and procedures, and administrative issues, subscribe to the American Journal of Alzheimer's Disease and Other Dementias® today!Read the American Journal of Alzheimer's Disease and Other Dementias® call for papers.

The mission of AJNR is to further knowledge in all aspects of neuroimaging, head and neck imaging, and spine imaging for neuroradiologists, radiologists, trainees, scientists, and associated professionals through print and/or electronic publication of quality peer-reviewed articles that lead to the highest standards in patient care, research, and education and to promote discussion of these and other issues through its electronic activities.

According to the most recent ranking of impact factors (from June 2010) in Journal Citation Reports, the American Journal on Intellectual and Developmental Disabilities (formerly the American Journal on Mental Retardation) is ranked No. 2 in “Special Education” and No. 2 in “Rehabilitation.” The premier journal in its field for more than 115 years, AJIDD publishes expert contributions on the treatment and prevention of intellectual disabilities. The Journal is an essential reference for researchers in the biological and health sciences, and a crucial addition to human services libraries.